#ES­MO22: As­traZeneca takes dif­fer­ent ap­proach to CT­LA-4 with bis­pe­cif­ic — but tox­i­c­i­ties re­main high

PARIS — Dur­ing a Sun­day morn­ing ES­MO pre­sen­ta­tion ses­sion on non-small cell lung can­cer in which the over­flow sec­tion over­flowed, As­traZeneca took the first two pre­sen­ta­tions …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER